NCT07631884
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 23 words
- Study sites: 0 to 1
- Start date changed from estimate of Jun 15, 2026 to May 12, 2026
- Secondary endpoints: details revised at 3 of 8 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Objective Response Rate, ORR
Timeframe: From the date of first study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 24months.
Secondary (8)
Duration of Response, DOR
Progression-Free Survival, PFS
Overall Survival, OS
Disease Control Rate, DCR
Best Overall Response, BOR
Show 3 moreShow less
Time to Response, TTR
Patient-reported outcomes, PROs
Adverse Events, AEs
Arms and interventions
Trastuzumab RezetecanExperimental
Participants will receive intravenous infusion of Trastuzumab Rezetecan on Day 1 of each 21-day treatment cycle. The dosage is 4.8 mg/kg per cycle; participants with a body weight of 85 kg or above will receive a fixed dose of 408 mg every 3 weeks.
Drugs: Trastuzumab Rezetecan
Sites
1 site in 1 country
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityShanghai, Shanghai Municipality, China